Search Within

Gopakumar Vasudeva Iyer

  1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (30)
  2. Genitourinary Oncology Service (30)
  3. Gynecologic Medicine Service (30)
  4. Solid Tumor Oncology Division (30)
  5. Gynecology Disease Management Team (23)
  6. GDMT, Medicine (22)

More Groups

People
  1. David Hyman (15)
  2. David Solit (14)
  3. Michael Berger (13)
  4. Rachel Grisham (13)
  5. Carol Aghajanian (12)
  6. James Harding (10)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (3)
  4. 2020 (2)
  5. 2019 (1)
  6. 2018 (6)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Clinical Cancer Research (2)
  3. Scientific Reports (2)
  4. Annals of Oncology (1)
  5. Cancer (1)
  6. Cancer Investigation (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. Nature Publishing Group (5)
  3. American Association for Cancer Research (3)
  4. Springer (2)
  5. American Medical Association (1)
  6. Cell Press (1)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save
  • Tumor inhibition by enzalutamide in a xenograft model of ovarian cancer
    Journal Article

    Park, B. Y.; Grisham, R. N.; den Hollander, B.; Thapi, D.; Berman, T.; de Stanchina, E.; Zhou, Q.; Iyer, G.; Aghajanian, C.; Spriggs, D. R.
    Cancer Investigation (2016)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase II "basket" trial
    Meeting Abstract

    Li, B. T.; Zauderer, M.; Chaft, J.; Drilon, A.; Eng, J.; Sima, C.; Makker, V.; Iyer, G.; Janjigian, Y.; Hyman, D.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Sylvester, B. E.; Won, H.; McDermott, G.; DeLair, D.; Ramirez, R.; Yao, Z.; Shen, R. L.; Dao, F.; Bogomolniy, F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Effect of enzalutamide (Enza) on androgen receptor (AR) positive (+) ovarian cancer
    Meeting Abstract

    Grisham, R. N.; Thapi, D.; Berman, T.; de Stanchina, E.; Zhou, Q.; Iasonos, A.; Iyer, G.; Aghajanian, C.; Spriggs, D. R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Hyman, D. M.; Aghajanian, C.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save
  • Targeted therapies for treatment of recurrent ovarian cancer
    Journal Article

    Grisham, R. N.; Hyman, D. M.; Iyer, G.
    Clinical Advances in Hematology & Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Garg, K.; DeLair, D.; Hyman, D. M.; Zhou, Q.; Iasonos, A.; Berger, M. F.; Dao, F.; Spriggs, D. R.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • A comprehensive analysis of BRAF and KRAS mutation status in low-grade serous (LGS) and serous borderline (SB) ovarian cancer (OC)
    Meeting Abstract

    Grisham, R. N.; Garg, K.; Zhou, Q.; Iasonos, A.; Berger, M. F.; Dao, F.; Hyman, D. M.; Levine, D. A.; Solit, D. B.; Aghajanian, C.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save